The World Health Organization said the risk of H5N1 spreading to humans is low but urged precautions. There is no evidence that the one human infection spread to anyone else, but when humans have been infected by animals, the virus is deadly, as 56% of the reported cases in humans ended in fatality. (Forbes)
Teva Pharmaceutical met industry forecasts, but its 2023 outlook left investors disappointed. For 2023, Teva forecast adjusted earnings per share of $2.25-$2.55 and revenue of $14.8-$15.4 billion, compared with adjusted EPS of $2.52 and revenue of $14.9 billion in 2022. Analysts had expected non-GAAP EPS of $2.52 and revenue of $15.2 billion. (Reuters)
The Next phase of breast cancer vaccine research began at the Cleveland Clinic. The vaccine is based on pre-clinical research led by the late Vincent Tuohy, Ph.D., who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic’s Lerner Research Institute. (WKYC)
Analysts said Bristol Myers Squibb and Merck are the top two biotech stocks to buy in February. In the biotech sector, there are plenty of these opportunities right now. Valuations have been hit hard as investors price in higher discount rates into their models. (The Motley Fool)
Texas sued the Biden administration for asking pharmacies to fill reproductive health prescriptions. The Biden administration said in July 2022 that refusing to fill prescriptions for drugs that could be used to terminate a pregnancy could violate federal law, regardless of various state bans on the procedure. (U.S. News & World Report)
